Suzanne Lentzsch, MD, PhD
Overview
Dr. Lentzsch is a Professor of Clinical Medicine and the Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York. She is at New York Presbyterian Hospital/ Columbia University Medical Center. After receiving her degrees from the Humboldt University/ Charité Berlin, Germany, she completed her residency and fellowship at Humboldt University. She did a research fellowship, studying the mechanism of action of thalidomide and its derivatives in multiple myeloma, in the Jerome Lipper Multiple Myeloma Center under the mentorship of Dr Kenneth Anderson at the Dana-Farber Cancer Institute, Boston, MA, USA.
Dr. Lentzsch was recruited in August 2004 to the University of Pittsburgh and University of Pittsburgh Cancer Institute (UPCI), PA, USA, and served as Clinical Director of the Multiple Myeloma Program at UPCI before accepting the position as Director of the Multiple Myeloma and Amyloidosis Program at Columbia University Medical Center. She cares primarily for patients with plasma cell dyscrasia including MGUS, Multiple Myeloma, Amyloidosis, POEMS and Waldenstrom's Macroglobulinemia.
Dr. Lentzsch is an internationally recognized expert in the field of Multiple Myeloma and Amyloidosis. She serves as a SWOG Myeloma Committee Member, SWOG Study Coordinator and International Myeloma Foundation "Black Swan Research Initiative" committee member. She is a member of the standing advisory board for the evaluation of Secondary Primary Malignancies associated with IMiDs.
Areas of Expertise / Conditions Treated
- Amyloidosis
- Bone Marrow Transplant
- MGUS (Monoclonal Gammopathy of Unknown Significance)
- Multiple Myeloma
- Peripheral Stem Cell Transplant
- POEMS Syndrome
- Waldenstrom's Disease
Academic Appointments
- Professor of Medicine
Administrative Titles
- Director, Multiple Myeloma and Amyloidosis Program
Hospital Affiliations
- NewYork-Presbyterian / Columbia University Irving Medical Center
- NewYork-Presbyterian Westchester
Languages
- German
Gender
- Female
Schedule an Appointment
Virtual Visits/Telehealth
Virtual Visits allow you to connect with your provider from the comfort, convenience, and safety of your own home.
Phone Appointments
Connect Patient Portal
For existing patients, login to make an appointment, view documentation or contact your care provider.
Location(s)
Insurance Accepted
Aetna
- Aetna Signature Administrators
- NYP Employee Plan
- NY Signature
- Student Health
Affinity Health Plan
- Medicaid Managed Care
AgeWell
- Medicare Managed Care
- Special Needs
Amerigroup of New Jersey
- New Jersey Services (Medicaid Managed Care)
Amida Care
- Special Needs
Cigna
- EPO
- Great West (National)
- HMO
- Medicare Managed Care
- POS
- PPO
Emblem/GHI
- Medicare Managed Care
- PPO
Emblem/HIP
- ConnectiCare
- EPO
- Essential Plan
- HMO
- Medicaid Managed Care
- Medicare Managed Care
- POS
- PPO
- Select Care (Exchange)
- Vytra
Empire Blue Cross/Blue Shield
- EPO
Empire Blue Cross Blue Shield HealthPlus
- Child/Family Health Plus
- Essential Plan
Fidelis Care
- Essential Plan
- Medicaid Managed Care
- Medicare Managed Care
Healthfirst
- Child/Family Health Plus
- Leaf (Exchange)
- Medicare Managed Care
Local 1199
- Local 1199
MagnaCare (National)
- MagnaCare
Medicare
- Railroad
- Traditional Medicare
Multiplan
- Multiplan
MVP Health Care
- Child/Family Health Plus
- Essential Plan
- HMO
- Medicaid Managed Care
Quality Health Management
- Quality Health Management
RiverSpring
- Special Needs
UnitedHealthcare
- Compass (Exchange)
- Empire Plan
- HMO
- Medicaid (Community Plan)
- Oxford Freedom
- Oxford HMO
- Oxford Liberty
- POS
- PPO
VNSNY CHOICE
- SelectHealth
WellCare
- Medicare Managed Care
World Trade Center Health Plan
- World Trade Center Health Plan
Credentials & Experience
Education & Training
- Humboldt University, Faculty of Medicine (Germany)
- Internship: Humboldt University, Faculty of Medicine (Germany)
- Residency: Humboldt University, Faculty of Medicine (Germany)
- Fellowship: Dana Farber Cancer Institute-Harvard Medical School
- Fellowship: Humboldt University, Faculty of Medicine (Germany)
Committees, Societies, Councils
- German Society of Cancer
- American Society of Hematology
- American Association for Cancer Reseach
- American Society of Clinical Oncology
- International Myeloma Working Group
- International Myeloma Society
- Herbert Irving Comprehensive Cancer Center in Lymphoid Development and Malignancy
- ECOG Auditor
- SWOG Study Coordinator
- SWOG Myeloma Committee Member
- Herbert Irving Comprehensive Cancer Center Protocol Review and Monitoring Committee
Honors & Awards
- 2014: Leukemia Lymphoma Society, Woman of the year Candidate
- 2014 - 2015: MMRF Laugh for Life Honorary Chair
- 2012: ASH Advocacy Leadership Institute
- 2012 - 2013: “Leukemia Diploma For a selection of worthy articlesin 2012/2013” by Editor in Chief, Leukemia
- 2012:Japanese Society of Hematology Appreciation Award
- 2009: UPCI Junior Scholar Award in Clinical Cancer Research
- 2005: Research Day Awardee, Junior Faculty Category, University of Pittsburgh School of Medicine, Department of Medicine Third Annual Research Day
Research
Dr Lentzsch' translational laboratory research work provided critical insights to understanding of the mechanism of action of thalidomide and IMiDs in multiple myeloma and bone disease. With the goal to bring findings from bench to beside, her current RO1 funded laboratory research investigates the role of metallo-proteinases in multiple myeloma bone disease in order to develop new strategies to target myeloma bone disease.
Dr Lentzsch is leading many phase 1, 2 and 3 clinical trials, including investigator-initiated studies for amyloidosis, newly diagnosed and relapsed/refractory multiple myeloma and for maintenance following transplant for multiple myeloma. She currently focuses on the evaluation of the monoclonal antibody 11-1F4 targeting amyloid directly and thereby inducing the break –up of amyloid. Further Dr. Lentzsch served as national principal investigator in Germany evaluating the role of lenalidomide in the treatment of relapsed Multiple Myeloma and is leading an international multicenter trial to evaluate the role of Xofigo in relapsed refractory multiple myeloma. As Co-Chair of the Pathways Committee, she played a major role in the development of the Multiple Myeloma Pathways at University Pittsburgh Medical Center.
Her research is funded by various grants and awards from e.g. the NIH, Pennsylvania Department of Health, the German Cancer Foundation, the Leukemia and Lymphoma Society , the Multiple Myeloma Research Foundation and the International Myeloma Foundation. Dr Lentzsch has published over 70 original articles, editorials, chapters, many as the lead or senior author, in such prestigious journals as Journal of Clinical Investigations, Blood, Cancer Research, and Leukemia.
For a complete list of publications, please visit PubMed.gov
Related News
- August 23, 2022
Topic
- February 24, 2020
Topic
